RxDoctor Payments Data

Brian Bennett, MD

Urology · Raleigh, NCNPI 1891766077

Payments from drug & device makers

$11,172in general payments, 2019–2025

Across 541 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Johnson & Johnson$2K
  • Myriad Genetic Laboratories, Inc.$871
  • Sumitomo Pharma America, Inc.$827
  • Astellas Pharma US Inc$742
  • AbbVie$460
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$10,91398%
  • Education$2592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,172 in reported general payments places this provider in the 80th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$322,893
Medicare patients
946
Services billed
12,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide74$790,369
ErleadaApalutamide22$315,713
GemtesaVibegron248$194,583
MyrbetriqMirabegron101$88,318
OrgovyxRelugolix18$47,682
Tamsulosin Hcl1,453$25,487
ElmironPentosan Polysulfate Sodium18$21,867
Abiraterone Acetate27$15,317
Silodosin118$10,693
Finasteride614$8,627
Dutasteride296$7,909
Potassium Citrate ErPotassium Citrate80$7,514
Testosterone41$4,521
Estradiol51$3,066
Trospium Chloride38$3,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$742$878,687175 claims
Johnson & JohnsonErleada$1,753$315,71322 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$827$242,265266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 434 urology providers in North Carolina.

Other urology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →